Magneto Thrombectomy Solutions
Thrombectomy Solutions
StartupMagneto Thrombectomy Solutions is a Or Yehuda-based startup in the Health Tech & Life Sciences sector, established in 2016. Thrombectomy Solutions. The company has raised a total of $1.85M across 5 funding rounds, currently at the Seed stage. Magneto Thrombectomy Solutions was founded by Yuval Taff. Key investors include Peregrine Ventures. The company has 1-10 employees. Core technologies: Semiconductors & Electronics.
With $1.85M in total funding, Magneto Thrombectomy Solutions is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQOr Yehuda
- DistrictCenter District
- Last RoundUndisclosed
- Peregrine Ventures
Yuval TaffCo-founder & CSO
1 article covered by sources including www.prnewswire.com.
What does Magneto Thrombectomy Solutions do?
Magneto is developing innovative thrombectomy solutions for the removal of blood clots in the vascular system. The Magneto catheters use electric fields to create an attraction with the target clot. When voltage is applied, the negatively charged ions of the clot are bonded to the active positive electrode of the catheter, creating a strong magnetic type of grip. This allows for clot removal without damaging the endoluminal surface of the vessel while lessening the chance of distal embolization. The fibrin content of a blood clot possesses high charge electrical density enabling strong adherence. Magneto's technology has been proven to be effective for all clot types - from acute- soft, red, Red Blood Cell-rich clots to chronic- firm, white, fibrin-rich clots. In-vitro tests have shown success in addressing a wide range of clot types with this proprietary technology. The eTrieve™ PE kit is custom designed for the pulmonary arteries. Using Magneto's large bore aspiration catheter, together with the eTrieve™ Catheter with its proprietary electric attachment technology, the system can remove both proximal and distal emboli with minimal artery interaction and less fragmentation. The company has demonstrated the safety and efficacy of its eTrieve PE Kit with its successful first-in-human (FIH) study. The results showed a significant reduction in right ventricular to left ventricular diameter (RV/LV) ratio and alleviation of symptoms associated with PE.
How much funding has Magneto Thrombectomy Solutions raised?
Magneto Thrombectomy Solutions has raised $1.85M in total funding across 5 rounds. The company is currently at the Seed stage. Key investors include Peregrine Ventures.
Who founded Magneto Thrombectomy Solutions?
Magneto Thrombectomy Solutions was founded in 2016 by Yuval Taff (Co-founder & CSO).
What sector is Magneto Thrombectomy Solutions in?
Magneto Thrombectomy Solutions operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Semiconductors & Electronics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Magneto Thrombectomy Solutions located?
Magneto Thrombectomy Solutions is based in Yehonatan Netanyahu Street 6, Or Yehuda, Israel, Center District.